全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

基于网络药理学及分子对接技术探讨黄芪甲苷治疗骨质疏松的作用机制研究
Mechanism of Astragaloside Intervention in Osteoporosis Based on Network Pharmacology and Molecular Docking Technology

DOI: 10.12677/HJMCe.2023.113025, PP. 204-211

Keywords: 网络药理学,分子对接,骨质疏松,黄芪甲苷
Network Pharmacology
, Molecular Docking, Osteoporosis, Astragaloside IV

Full-Text   Cite this paper   Add to My Lib

Abstract:

目的:采用网络药理学及分子对接方法探讨黄芪甲苷治疗骨质疏松的作用机制。方法:通过文献研究及Swiss数据库筛选得到黄芪甲苷活性成分并分析相关作用蛋白靶点,借助OMIM、GeneCards、DRUG BANK、DisGeNet等数据库分析骨质疏松基因靶点,并取交集;借助STRING数据库及Cytoscape软件构建PPI网络关系并得到黄芪甲苷干预骨质疏松关键靶点;借助metascape数据库进行生物富集分析;使用autodock软件进行核心化合物–蛋白分子对接。结果:得到黄芪甲苷涉及268个蛋白靶点,其中与骨质疏松相关核心靶点为ALB、IGF1、SRC、ESR1等;在分子对接实验中,Affinity平均值为?6.49 kcal·mol?1,最小值为?13.46 kcal·mol?1证明黄芪甲苷与核心蛋白有较大结合能;KEGG富集分析结果显示关键通路为AGE-RAGE signaling pathway、FoxO signaling pathway、PI3K-Akt sig-naling pathway等。结论:黄芪甲苷干预骨质疏松依靠多通路、多靶点协调作用,其主要通过ALB、IGF1、SRC、ESR1等蛋白作用与AGE-RAGE signaling pathway、FoxO signaling pathway、PI3K-Akt signaling pathway等通路发挥治疗骨质疏松作用。
Objective: To investigate the mechanism of astragaloside in the treatment of osteoporosis by network pharmacology and molecular docking. Methods: The active ingredients of astragaloside were obtained through literature review and Swiss database screening, and the related protein targets were analyzed. The osteoporosis gene targets were analyzed by OMIM, GeneCards, DRUG BANK, DisGeNet and other databases, and the intersection was selected. The PPI network relationship was constructed by using STRING database and Cytoscape software, and the key targets of astragaloside intervention in osteoporosis were obtained. Bioenrichment analysis was carried out with metascape database. Autodock software was used for core compound-protein molecular docking. Results: Astragaloside involved 268 protein targets, among which the core targets related to osteoporosis were ALB, IGF1, SRC, ESR1, etc. In the molecular docking experiment, the average value of Affinity was ?6.49 kcal·mol?1, and the minimum value was ?13.46 kcal·mol?1, indicating that astragaloside had greater binding energy with core protein. KEGG enrichment analysis showed that the key pathways were AGE-RAGE signaling pathway, FoxO signaling pathway, PI3K-Akt signaling pathway, etc. Conclusion: The intervention of astragaloside in osteoporosis depends on multi-pathway and multi-target coordination. It mainly plays a role in the treatment of osteoporosis through the interaction of ALB, IGF1, SRC, ESR1 and other proteins with AGE-RAGE signaling pathway, FoxO signaling pathway, PI3K-Akt signaling pathway and other pathways.

References

[1]  中华中医药学会. 骨质疏松性骨折中医诊疗指南[J]. 中医正骨, 2023, 35(1): 1-9.
[2]  王峰. 骨质疏松性椎体压缩骨折的临床相关研究和意义[D]: [博士学位论文]. 石家庄: 河北医科大学, 2021.
[3]  段小云, 仲瑞雪, 吴传红, 季欧. 基于数据挖掘和网络药理学探讨中医药治疗骨质疏松症的用药规律及机制[J]. 中国医院用药评价与分析, 2023, 23(2): 162-168.
[4]  成鹏, 白银亮, 胡彩莉, 连佛彦, 周海宇. 黄芪甲苷通过调控FoxO3a/Wnt2/β-catenin通路抑制去卵巢大鼠骨质疏松的作用[J]. 中国实验方剂学杂志, 2018, 24(15): 161-166.
[5]  姜涛, 邵敏, 黄永青, 等. 骨质疏松症的诊疗进展[J]. 当代医学, 2018, 24(30): 182-186.
[6]  张清文, 卫俊杰. 糖尿病性骨质疏松症发病机制的研究进展[J]. 现代临床医学, 2022, 48(5): 378-380.
[7]  唐中尧, 李华, 徐祖健. 中药治疗骨质疏松症的用药规律研究[J]. 中医正骨, 2019, 31(1): 20-22+25.
[8]  宋家彬, 赵丽, 刘文红. 基于辨证理念的骨质疏松症中医治疗进展[J]. 内蒙古中医药, 2020, 39(10): 166-168.
[9]  王璇, 徐天成. 以太阳经为例浅谈《伤寒论》六经与《黄帝内经》六经的异同[J]. 国际中医中药杂志, 2016, 38(3): 197-199.
[10]  邓荣, 唐本夫, 钟欣欣. 基于网络药理学研究黄芪抗骨质疏松作用机制[J]. 中医药临床杂志, 2020, 32(5): 890-896.
[11]  王新祥, 张允岭, 黄启福. 对骨质疏松症中医主要病机和现代病因学的认识与探讨[J]. 中西医结合学报, 2010, 8(12): 1119-1123.
[12]  范志梁, 田兴中, 顾春松, 牛建均, 刘春艳, 王焕珍, 国业东, 李文, 陈云志, 柴艺汇. 黄芪调节维生素D介导OPG/RANKL/RANK信号通路对维甲酸诱导骨质疏松C57BL/6J小鼠股骨的影响[J]. 时珍国医国药, 2023, 34(4): 831-834.
[13]  魏?吴普, 述. 神农本草经[M]. 南宁: 广西科学技术出版社, 2016: 31.
[14]  国家药典委员会. 中国药典[S]. 北京: 中国医药科技出版社, 2020: 315-316.
[15]  黄海涛, 梁单, 金昱. 黄芪甲苷拮抗过氧化氢引起的小鼠成骨细胞凋亡作用[J]. 延边大学医学学报, 2012, 35(2): 86-91.
[16]  丁伟逸, 张霆, 林越, 严寅杰. 基于网络药理学探讨益气化瘀补肾方治疗骨延迟愈合的作用机制[J]. 实用中西医结合临床, 2022, 22(8): 7-13+24.
[17]  Tanaka, S., Amling, M., Neff, L., Peyman, A., Uhlmann, E., Levy, J.B. and Baron, R. (1996) c-Cbl Is Downstream of c-Src in a Signalling Pathway Necessary for Bone Resorption. Na-ture, 383, 528-531.
https://doi.org/10.1038/383528a0
[18]  Peng, X.D., Xu, P.Z., Chen, M.L., et al. (2003) Dwarf-ism, Impaired Skin Development, Skeletal Muscle Atrophy, Delayed Bone Development, and Impeded Adipogenesis in Mice Lacking Akt1 and Akt2. Genes & Development, 17, 1352-1365.
https://doi.org/10.1101/gad.1089403
[19]  王海彬, 王军舰, 黄辉, 刘琳, 刘少军, 徐传毅, 何伟, 樊粤光, 黄志伟. 黄芪注射液对雌激素受体的激活作用研究[J]. 时珍国医国药, 2006(11): 2113-2115.
[20]  Asadipooya, K. and Uy, E.M. (2019) Advanced Glycation End Prod-ucts (AGEs), Receptor for AGEs, Diabetes, and Bone: Review of the Literature. Journal of the Endocrine Society, 3, 1799-1818.
https://doi.org/10.1210/js.2019-00160
[21]  Xi, J.C., Zang, H.Y., Guo, L.X., Xue, H.B., Liu, X.D., Bai, Y.B. and Ma, Y.Z. (2015) The PI3K/AKT Cell Signaling Pathway Is Involved in Regulation of Osteoporosis. Journal of Receptor and Signal Transduction Research, 35, 640-645.
https://doi.org/10.3109/10799893.2015.1041647
[22]  杨亚军, 崔燎. FoxO/Wnt通路在氧化应激介导的骨质疏松中的调控机制[J]. 中国药理学通报, 2013, 29(1): 27-30.

Full-Text

comments powered by Disqus

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133

WeChat 1538708413